Orchestra BioMed Holdings (OBIO) Preferred Stock Liabilities (2020 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Preferred Stock Liabilities for 5 consecutive years, with $2.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Preferred Stock Liabilities changed N/A year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (changed N/A YoY), while the FY2025 annual figure was $2.7 million, changed N/A from the prior year.
• Preferred Stock Liabilities climbed to $2.8 million in Q1 2026 per OBIO's latest filing, from $2.7 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $160.1 million in Q2 2022 and bottomed at $2.7 million in Q4 2025.
• Historically, Preferred Stock Liabilities has averaged $76.8 million across 3 years, with a median of $67.7 million in 2022.
• On a YoY basis, Preferred Stock Liabilities climbed as much as 5.89% in 2022 and fell as far as 57.7% in 2022.
• Orchestra BioMed Holdings' Preferred Stock Liabilities stood at $67.7 million in 2022, then plunged by 95.94% to $2.7 million in 2025, then climbed by 1.27% to $2.8 million in 2026.
• Business Quant data shows OBIO's Preferred Stock Liabilities at $2.8 million in Q1 2026, $2.7 million in Q4 2025, and $67.7 million in Q4 2022.